

Neurotrophic Keratopathy

Neurotrophic keratopathy (NK), also known as neurotrophic keratitis, is a disease that affects corneal sensitivity.¹ Neurotrophic keratopathy is rare, affecting approximately 5 in 10,000 patients.² If NK remains undetected and untreated, it can progress and lead to blindness.³

Neurotrophic keratopathy is defined as dysfunction of corneal sensory innervation that results in dysregulation of the corneal nerve and cellular function.^{1,4-6} Corneal nerves act in maintaining corneal epithelial cells via the protective blink reflex and tear secretion. Corneal nerves release neuropeptides that provide trophic support for epithelial cells. In turn, corneal epithelial cells support the neurons through their release of neurotrophic factors, including nerve growth factor (Figure).^{1,4-6} Loss of this neuronal homeostasis leads to loss of corneal sensation (the hallmark of NK), corneal epithelial breakdown, and, ultimately, keratolysis if left untreated.^{1,5,6} Table 1 gives an overview of the causes of NK.^{1,6}




Figure. Corneal nerves and corneal epithelial cells interact in a mutually supportive relationship to maintain neuronal homeostasis^{1,4-6}

Table 1. Overview of the Causes of Neurotrophic Keratopathy^{1,6}

Infectious and Noninfectious Keratitis	Iatrogenic	Congenital Diseases
<ul style="list-style-type: none"> • Herpes simplex keratitis • Herpes zoster keratitis • Acanthamoeba keratitis • Chemical injury • Thermal injury • Contact lenses 	<ul style="list-style-type: none"> • Ocular surgery • Keratoplasty • Corneal refractive surgery • Collagen cross-linking • Retinal photocoagulation • Orbital surgery • Surgery affecting trigeminal nerve 	<ul style="list-style-type: none"> • Familial dysautonomia • Goldenhar-Gorlin syndrome • Congenital corneal hypoesthesia • Möbius syndrome
Systemic Diseases	Medication Induced	Trigeminal Nerve Palsy
<ul style="list-style-type: none"> • Diabetes • Multiple sclerosis • Leprosy 	<ul style="list-style-type: none"> • Anesthetic abuse • Topical medication toxicity • Chronic use of antipsychotic drugs • Chronic use of antihistamines 	<ul style="list-style-type: none"> • Traumatic injury • Intracranial and orbital malignancy • Postsurgical palsy • Aneurysm and cerebrovascular accident

Clinical signs of NK include punctate epithelial erosions, irregular corneal epithelium, epithelial defects, subepithelial haze, stromal scarring and ulceration, and corneal perforation.^{1,3} These have been traditionally classified by Mackie as NK stages 1 to 3 (Table 2).^{1,3,7}

Table 2. Stages of Neurotrophic Keratopathy^{1,3,7}

Stage	Examination Findings	Corneal Sensation
1: Mild	<ul style="list-style-type: none"> • Punctate keratopathy • Epithelial hyperplasia and irregularity • Superficial neovascularization • Stromal scarring 	Reduced or aberrant corneal sensation
2: Moderate	<ul style="list-style-type: none"> • Persistent epithelial defect • Loose and opaque epithelium around the defect • Rolled edges of defect • Stromal swelling • Anterior chamber reaction • Sterile hypopyon (rare) 	Corneal anesthesia
3: Severe	<ul style="list-style-type: none"> • Stromal involvement (thinning, perforation) 	Corneal anesthesia

Treatment of NK depends on its severity and is often a stepwise approach, involving a combination of drugs, devices, and surgical procedures.^{1,2,6} Recombinant human nerve growth factor (cenegermin) is the only US Food and Drug Administration–approved therapy for NK and has been shown to promote corneal healing.⁸⁻¹⁰ Other treatments include artificial tears, serum drops, and anti-inflammatory drugs, tarsorrhaphy, punctal plugs, and amniotic membrane grafts.^{1,2,6}

References

1. Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. *Prog Retin Eye Res.* 2018;66:107-131.
2. Dana R, Farid M, Gupta PK, et al. Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy. *BMC Ophthalmol.* 2021;21(1):327.
3. Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. *Eye (Lond).* 2003;17(8):989-995.
4. Saad S, Abdelmassih Y, Saad R, et al. Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes. *Ocul Surf.* 2020;18(2):231-236.
5. Sheha H, Tighe S, Hashem O, Hayashida Y. Update on cenegermin eye drops in the treatment of neurotrophic keratitis. *Clin Ophthalmol.* 2019;13:1973-1980.
6. Versura P, Giannaccare G, Pellegrini M, Sebastiani S, Campos EC. Neurotrophic keratitis: current challenges and future prospects. *Eye Brain.* 2018;10:37-45.
7. Mackie IE. Neuroparalytic keratitis. In: Fraunfelder F, Roy FH, Meyer SM, eds. *Current Ocular Therapy.* WB Saunders; 1995:452-454.
8. Bonini S, Lambiase A, Rama P, et al; REPARO Study Group. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. *Ophthalmology.* 2018;125(9):1332-1343.
9. Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. *Ophthalmology.* 2020;127(1):14-26.
10. Cenegermin-bkbj. Package insert. US National Library of Medicine. Updated November 1, 2022. Accessed March 17, 2023. <https://dailymed.nlm.nih.gov/dailymed>

Raising Suspicion for Neurotrophic Keratopathy

It is imperative to identify and treat NK and other diseases affecting the corneal sensation early to avoid disease progression, invasive measures, and adverse patient outcomes.

Any of the following should raise suspicion of reduced or absent corneal sensitivity^{1,2}:

- Persistent or painless epithelial defect
- Vision changes not ascribed to the retina or lens
- Photophobia
- History of the following:
 - Herpetic eye disease
 - Trigeminal nerve damage
 - Corneal procedures
- Risk factors:
 - Poorly controlled diabetes
 - Reduced blink

Corneal Sensitivity Testing

Methods of assessing corneal sensation³:

- “Wisp” of cotton, dental floss
 - Performed easily in the clinic
 - Patient’s reaction is noted and compared between each eye
- Cochet-Bonnet esthesiometer
 - Different lengths (60 to 5 mm) of nylon filament applied to the cornea
 - The longer the length, the higher the sensitivity
- Belmonte noncontact gas esthesiometer
 - Cornea stimulated with calibrated air jet; blink response is observed
 - Used only in study settings

**If you suspect possible lowered ocular surface sensitivity,
DELAY ADMINISTERING ANESTHETIZING EYE DROPS
and refer to the clinic physician.**

Qualitative Method

Using a cotton-tipped applicator or dental floss, compare the sensation in each eye. Approach the patient from the side and test all 4 quadrants (**Figure**).⁴ Document the sensation in each section as normal, reduced, or absent.




Figure. Testing corneal reflex⁴
Reprinted with permission from Alpert JN. Neurologic examination. In: Alpert JN. *The Neurologic Diagnosis*. 2nd ed. Springer; 2019:53-162. Copyright 2019 by Springer Nature.

References

1. Dana R, Farid M, Gupta PK, et al. Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy. *BMC Ophthalmol*. 2021;21(1):327.
2. Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. *Eye (Lond)*. 2003;17(8):989-995.
3. Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. *Prog Retin Eye Res*. 2018;66:107-131.
4. Alpert JN. Neurologic examination. In: Alpert JN. *The Neurologic Diagnosis*. 2nd ed. Springer; 2019:53-162.